Current Recommendations for the Management of Cancer-Associated Venous Thromboembolism

1. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122:1712-1723. doi: 10.1182/blood-2013-04-460121.10.1182/blood-2013-04-460121 Search in Google Scholar

2. Abdol Razak NB, Jones G, Bhandari M, et al. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers. 2018;10:380. doi: 10.3390/cancers10100380.10.3390/cancers10100380 Search in Google Scholar

3. Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;66:458-464. doi: 10.1001/archinte.166.4.458.10.1001/archinte.166.4.458 Search in Google Scholar

4. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-1850. doi: 10.1056/NEJM200012213432504.10.1056/NEJM200012213432504 Search in Google Scholar

5. Wójtowicz M, Rękas-Wójcik A, Lipa A, et al. Thrombotic complications – prevention and treatment of venous thromboembolism in cancer patients. Journal of Pre-Clinical and Clinical Research. 2012;6:84-87. Search in Google Scholar

6. Streiff MB, Holmstrom B, Angelini D, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16:1289-1303. doi: 10.6004/jnccn.2018.0084.10.6004/jnccn.2018.0084 Search in Google Scholar

7. Navi BB, Reiner AS, Kamel H, et al. Risk of Arterial Thromboembolism in Patients With Cancer. J Am Coll Cardiol. 2017;70:926-938. doi: 10.1016/j.jacc.2017.06.047.10.1016/j.jacc.2017.06.047 Search in Google Scholar

8. Levi M. Management of cancer-associated disseminated intravascular coagulation. Thrombo Res. 2016;140:S66-S70. doi: 10.1016/S0049-3848(16)30101-3.10.1016/S0049-3848(16)30101-3 Search in Google Scholar

9. Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016;10:649. doi: 10.3332/ecancer.2016.649.10.3332/ecancer.2016.649 Search in Google Scholar

10. Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125:S1-S7. doi: 10.1016/S0049-3848(10)00227-6.10.1016/S0049-3848(10)00227-6 Search in Google Scholar

11. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907. doi: 10.1182/blood-2007-10-116327.10.1182/blood-2007-10-116327238412418216292 Search in Google Scholar

12. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377-5382. doi: 10.1182/blood-2010-02-270116.10.1182/blood-2010-02-27011620829374 Search in Google Scholar

13. Verso M, Agnelli G, Barni S, et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291-292. doi: 10.1007/s11739-012-0784-y.10.1007/s11739-012-0784-y22547369 Search in Google Scholar

14. Pelzer U, Sinn M, Stieler J, et al. Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy? Dtsch Med Wochenschr. 2013;138:2084-2088. doi: 10.1055/s-0033-1349608.10.1055/s-0033-134960824085361 Search in Google Scholar

15. Muñoz Martín AJ, Ortega I, Font C, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118:1056-1061. doi: 10.1038/s41416-018-0027-8.10.1038/s41416-018-0027-8593110329588512 Search in Google Scholar

16. Khorana AA, DeSancho MT, Liebman H, et al. Prediction and Prevention of Cancer-Associated Thromboembolism. Oncologist. 2021;26:e2-e7. doi: 10.1002/onco.13569.10.1002/onco.13569779420333274815 Search in Google Scholar

17. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE. Incidence of venous thromboembolism in patients hospitalized with cancer. Amer J Med. 2006;119:60-68. doi: 10.1016/j.amjmed.2005.06.058.10.1016/j.amjmed.2005.06.05816431186 Search in Google Scholar

18. Dickmann B, Ahlbrecht J, Pabinger I. Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study. Haematologica. 2013;98:1309-1314. doi: 10.3324/haematol.2012.073338.10.3324/haematol.2012.073338372991323585523 Search in Google Scholar

19. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-722. doi: 10.1001/jama.293.6.715.10.1001/jama.293.6.71515701913 Search in Google Scholar

20. Næss IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5:692-699. doi: 10.1111/j.1538-7836.2007.02450.x.10.1111/j.1538-7836.2007.02450.x17367492 Search in Google Scholar

21. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110:2339-2346. doi: 10.1002/cncr.23062.10.1002/cncr.2306217918266 Search in Google Scholar

22. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncology. 2006;24:484-490. doi: 10.1200/JCO.2005.03.8877.10.1200/JCO.2005.03.887716421425 Search in Google Scholar

23. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg. 2006;243:89-95. doi: 10.1097/01.sla.0000193959.44677.48.10.1097/01.sla.0000193959.44677.48144997916371741 Search in Google Scholar

24. Simanek R, Vormittag R, Ay C, et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost. 2010;8:114-120. doi: 10.1111/j.1538-7836.2009.03680.x.10.1111/j.1538-7836.2009.03680.x19889150 Search in Google Scholar

25. Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010;126:113-118. doi: 10.1016/j. thromres.2010.05.012. Search in Google Scholar

26. Dai H, Zhou H, Sun Y, et al. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. Biomed Rep. 2018;9:453-457. doi: 10.3892/br.2018.1151.10.3892/br.2018.1151620104730402229 Search in Google Scholar

27. Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res. 2004;10:7238-7243. doi: 10.1158/1078-0432.CCR-04-0445.10.1158/1078-0432.CCR-04-044515534097 Search in Google Scholar

28. Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers (Basel). 2019;11:95. doi: 10.3390/cancers11010095.10.3390/cancers11010095635624730650562 Search in Google Scholar

29. Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis. 2009;20:170-175. doi: 10.1097/MBC.0b013e32831bc2de.10.1097/MBC.0b013e32831bc2de19276795 Search in Google Scholar

30. Kondo S, Sasaki M, Hosoi H, et al. Incidence and risk factors for venous thromboembolism in patients with pretreated advanced pancreatic carcinoma. Oncotarget. 2018;9:16883-16890. doi: 10.18632/oncotarget.24721.10.18632/oncotarget.24721590829229682191 Search in Google Scholar

31. Park K, Ryoo BY, Ryu MH, et al. Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. World J Gastrointest Oncol. 2017;9:176-183. doi: 10.4251/wjgo.v9.i4.176.10.4251/wjgo.v9.i4.176539030328451065 Search in Google Scholar

32. Wu J, Fu Z, Liu G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine. 2017;96:e7062. doi: 10.1097/MD.0000000000007062.10.1097/MD.0000000000007062548419128640083 Search in Google Scholar

33. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112:2703-2708. doi: 10.1182/blood-2008-02-142422.10.1182/blood-2008-02-14242218539899 Search in Google Scholar

34. Di Nisio M, Ferrante N, De Tursi M, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010;104:1049-1054. doi: 10.1160/TH10-05-0277.10.1160/TH10-05-027720806119 Search in Google Scholar

35. Khorana AA, Dalal M, Lin J, et al. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119:648-655. doi: 10.1002/cncr.27772.10.1002/cncr.2777222893596 Search in Google Scholar

36. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 2005;103:994-999. doi: 10.1002/cncr.20893.10.1002/cncr.2089315666321 Search in Google Scholar

37. Cunningham D, Starling N, Rao S, et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. N Engl J Med. 2008;358:36-46. doi: 10.1056/NEJMoa073149.10.1056/NEJMoa07314918172173 Search in Google Scholar

38. John AH. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12:464-474. doi: 10.1038/nrcardio.2015.83.10.1038/nrcardio.2015.83462429826076949 Search in Google Scholar

39. Lee AYY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404-1408. doi: 10.1200/JCO.2005.03.5600.10.1200/JCO.2005.03.560016549834 Search in Google Scholar

40. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;00:3484-3488. doi: 10.1182/blood-2002-01-0108.10.1182/blood-2002-01-010812393647 Search in Google Scholar

41. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153. doi: 10.1056/NEJMoa025313.10.1056/NEJMoa02531312853587 Search in Google Scholar

42. Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314:677-686. doi: 10.1001/jama.2015.9243.10.1001/jama.2015.924326284719 Search in Google Scholar

43. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE Disease: CHEST guideline and expert panel eport. Chest. 2016;149:315-352. doi: 10.1016/j.chest.2015.11.026.10.1016/j.chest.2015.11.026 Search in Google Scholar

44. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med. 2002;162:1729-1735. doi: 10.1001/archinte.162.15.1729.10.1001/archinte.162.15.1729 Search in Google Scholar

45. Deitcher SR, Kessler CM, Merli G, et al. ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12:389-396. doi: 10.1177/1076029606293692.10.1177/1076029606293692 Search in Google Scholar

46. Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119:1062-1072. doi: 10.1016/j.amjmed.2006.02.022.10.1016/j.amjmed.2006.02.022 Search in Google Scholar

47. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452-e466. doi: 10.1016/S1470-2045(16)30369-2.10.1016/S1470-2045(16)30369-2 Search in Google Scholar

48. Farge D, Frere C, Connors JM, et al. International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566-e581. doi: 10.1016/S1470-2045(19)30336-5.10.1016/S1470-2045(19)30336-5 Search in Google Scholar

49. Hakoum MB, Kahale LA, Tsolakian IG, et al. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;1:CD006649. doi: 10.1002/14651858.CD006649.pub7.10.1002/14651858.CD006649.pub7638933929363105 Search in Google Scholar

50. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev. 2017;2:CD001100. doi: 10.1002/14651858. CD001100.pub4.10.1002/14651858 Search in Google Scholar

51. Key NS, Khorana AA, Kuderer NM, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38:496-520. doi: 10.1200/JCO.19.01461.10.1200/JCO.19.0146131381464 Search in Google Scholar

52. Mazzolai L, Aboyans V, Ageno W, et al. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208-4218. doi: 10.1093/eurheartj/ehx003.10.1093/eurheartj/ehx00328329262 Search in Google Scholar

53. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624. doi: 10.1056/NEJMoa1711948.10.1056/NEJMoa171194829231094 Search in Google Scholar

54. Young AM, Marshall A, Thirlwall J, et al: Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36:2017-2023. doi: 10.1200/JCO.2018.78.8034.10.1200/JCO.2018.78.803429746227 Search in Google Scholar

55. Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019;173:158-163. doi: 10.1016/j.thromres.2018.02.144.10.1016/j.thromres.2018.02.144611965529506866 Search in Google Scholar

56. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35:3240-3261. doi: 10.1200/JCO.2017.74.4789.10.1200/JCO.2017.74.478928759346 Search in Google Scholar

57. Muñoz Martín AJ, Gallardo Díaz E, García Escobar I, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer Clin Transl Oncol. 2020;22:171-186. doi: 10.1007/s12094-019-02263-z.10.1007/s12094-019-02263-z31981080 Search in Google Scholar

58. Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN study. J Thromb Haemost. 2015;13:1028-1035. doi: 10.1111/jth.12923.10.1111/jth.1292325827941 Search in Google Scholar

59. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90-96. doi: 10.1016/j. thromres. Search in Google Scholar

60. Zurawska U, Parasuraman S, Goldhaber SZ. Prevention of pulmonary embolism in general surgery patients. Circulation. 2007;115:e302-e307. doi: 10.1161/CIRCULATIONAHA. Search in Google Scholar

61. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-980. doi: 10.1056/NEJMoa012385.10.1056/NEJMoa01238511919306 Search in Google Scholar

62. Bustos Merlo AB, Arcelus Martınez JI, Turiño Luque JD, et al. Form of presentation, natural history and course of postoperative venous thromboembolism in patients operated on for pelvic and abdominal cancer. Analysis of the RIETE registry. Cir Esp. 2017;95:328-334. doi: 10.1016/j. ciresp.2017.05.006. Search in Google Scholar

63. Fagarasanu A, Alotaibi GS, Hrimiuc R, et al. Role of extended thromboprophylaxis after abdominal and pelvic surgery in cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2016;23:1422-1430. doi: 10.1245/s10434-016-5127-1.10.1245/s10434-016-5127-126887853 Search in Google Scholar

64. Di Nisio M, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2016;12:CD008500. doi: 10.1002/14651858.CD008500.pub4.10.1002/14651858.CD008500.pub4646393727906452 Search in Google Scholar

65. Khorana AA, Francis CW, Kuderer NM, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;151:89-95. doi: 10.1016/j.thromres.2017.01.009.10.1016/j.thromres.2017.01.00928139259 Search in Google Scholar

66. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720-728. doi: 10.1056/NEJMoa1814630.10.1056/NEJMoa181463030786186 Search in Google Scholar

67. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711-719. doi: 10.1056/NEJMoa1814468.10.1056/NEJMoa181446830511879 Search in Google Scholar

68. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol. 2003;21:3665-3675. doi: 10.1200/JCO.2003.08.008.10.1200/JCO.2003.08.00814512399 Search in Google Scholar

69. Kahale LA, Tsolakian IG, Hakoum MB, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2018;6:CD006468. doi: 10.1002/14651858. CD006468.pub6.10.1002/14651858 Search in Google Scholar

70. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24:1404-1408. doi: 10.1200/JCO.2005.03.5600.10.1200/JCO.2005.03.560016549834 Search in Google Scholar

71. Saber W, Moua T, Williams EC, et al. Risk factors of catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9:312-319. doi: 10.1111/j.1538-7836.2010.04126.x.10.1111/j.1538-7836.2010.04126.x428279621040443 Search in Google Scholar

72. Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (the Catheter study). J Thromb Haemost. 2007;5:1650-1653. doi: 10.1111/j.1538-7836.2007.02613.x.10.1111/j.1538-7836.2007.02613.x17488349 Search in Google Scholar

73. Kreuziger LB, Ageno W, Lee A. Management of incidental splanchnic vein thrombosis in cancer patients. Hematology Am Soc Hematol Educ Program. 2014;2014:318-320. doi: 10.1182/asheducation-2014.1.318.10.1182/asheducation-2014.1.31825696872 Search in Google Scholar

74. Ihaddadene R, Le Gal G, Delluc A, et al. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014;134:93-95. doi: 10.1016/j.thromres.2014.04.028.10.1016/j.thromres.2014.04.02824835673 Search in Google Scholar

75. Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760-765. doi: 10.1111/j.1538-7836.2009.03326.x.10.1111/j.1538-7836.2009.03326.x19245418 Search in Google Scholar

76. Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost. 2018;2:664-669. doi: 10.1002/rth2.12111.10.1002/rth2.12111617871330349884 Search in Google Scholar